JOHNSON & JOHNSON
JNJAPI behind this page
JNJ Q2 2025 request
Playground key active
/api/financials?ticker=JNJ&year=2025&quarter=2
Pick an endpoint and run the request.Income Statement
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Revenue | 23,743 | 22,447 | +5.8% |
Show Product Lines breakouts |
|||
| ADVANCED · MEDTECH | 477 | 466 | +2.4% |
| ADVANCED · MEDTECH | 687 | 675 | +1.8% |
| ADVANCED · MEDTECH | 1,164 | 1,141 | +2.0% |
| CAPLYTA · Innovative Medicine | 211 | — | — |
| CAPLYTA · Innovative Medicine | 211 | — | — |
| CARVYKTI · Innovative Medicine | 358 | 167 | +114.4% |
| CARVYKTI · Innovative Medicine | 81 | 20 | +305.0% |
| CARVYKTI · Innovative Medicine | 439 | 186 | +136.0% |
| CONCERTA / methylphenidate · Innovative Medicine | 24 | 34 | -29.4% |
| CONCERTA / methylphenidate · Innovative Medicine | 139 | 129 | +7.8% |
| CONCERTA / methylphenidate · Innovative Medicine | 164 | 163 | +0.6% |
| CONTACT LENSES / OTHER · MEDTECH | 429 | 409 | +4.9% |
| CONTACT LENSES / OTHER · MEDTECH | 536 | 509 | +5.3% |
| CONTACT LENSES / OTHER · MEDTECH | 965 | 918 | +5.1% |
| DARZALEX · Innovative Medicine | 2,017 | 1,641 | +22.9% |
| DARZALEX · Innovative Medicine | 1,521 | 1,237 | +23.0% |
| DARZALEX · Innovative Medicine | 3,539 | 2,878 | +23.0% |
| EDURANT/rilpivirine · Innovative Medicine | 6 | 8 | -25.0% |
| EDURANT/rilpivirine · Innovative Medicine | 354 | 288 | +22.9% |
| EDURANT/rilpivirine · Innovative Medicine | 360 | 297 | +21.2% |
| ERLEADA · Innovative Medicine | 378 | 318 | +18.9% |
| ERLEADA · Innovative Medicine | 530 | 418 | +26.8% |
| ERLEADA · Innovative Medicine | 908 | 736 | +23.4% |
| GENERAL · MEDTECH | 567 | 528 | +7.4% |
| GENERAL · MEDTECH | 825 | 818 | +0.9% |
| GENERAL · MEDTECH | 1,391 | 1,346 | +3.3% |
| HIPS · MEDTECH | 271 | 265 | +2.3% |
| HIPS · MEDTECH | 150 | 152 | -1.3% |
| HIPS · MEDTECH | 421 | 417 | +1.0% |
| IMBRUVICA · Innovative Medicine | 239 | 246 | -2.8% |
| IMBRUVICA · Innovative Medicine | 496 | 525 | -5.5% |
| IMBRUVICA · Innovative Medicine | 735 | 770 | -4.5% |
| INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA · Innovative Medicine | 732 | 784 | -6.6% |
| INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA · Innovative Medicine | 260 | 269 | -3.3% |
| INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA · Innovative Medicine | 992 | 1,054 | -5.9% |
| KNEES · MEDTECH | 226 | 230 | -1.7% |
| KNEES · MEDTECH | 164 | 163 | +0.6% |
| KNEES · MEDTECH | 389 | 394 | -1.3% |
| OPSUMIT/OPSYNVI · Innovative Medicine | 403 | 376 | +7.2% |
| OPSUMIT/OPSYNVI · Innovative Medicine | 180 | 171 | +5.3% |
| OPSUMIT/OPSYNVI · Innovative Medicine | 582 | 548 | +6.2% |
| OTHER IMMUNOLOGY · Innovative Medicine | 8 | 2 | +300.0% |
| OTHER IMMUNOLOGY · Innovative Medicine | 0 | 0 | — |
| OTHER IMMUNOLOGY · Innovative Medicine | 8 | 2 | +300.0% |
| OTHER INFECTIOUS DISEASES · Innovative Medicine | 2 | 5 | -60.0% |
| OTHER INFECTIOUS DISEASES · Innovative Medicine | 45 | 227 | -80.2% |
| OTHER INFECTIOUS DISEASES · Innovative Medicine | 47 | 233 | -79.8% |
| OTHER NEUROSCIENCE · Innovative Medicine | 45 | 57 | -21.1% |
| OTHER NEUROSCIENCE · Innovative Medicine | 226 | 237 | -4.6% |
| OTHER NEUROSCIENCE · Innovative Medicine | 270 | 294 | -8.2% |
| Other Oncology · Innovative Medicine | 50 | 37 | +35.1% |
| Other Oncology · Innovative Medicine | 42 | 45 | -6.7% |
| Other Oncology · Innovative Medicine | 93 | 83 | +12.0% |
| Other · Innovative Medicine | 155 | 129 | +20.2% |
| Other · Innovative Medicine | 16 | 17 | -5.9% |
| Other · Innovative Medicine | 154 | 176 | -12.5% |
| Other · Innovative Medicine | 40 | 49 | -18.4% |
| Other · Innovative Medicine | 309 | 305 | +1.3% |
| Other · Innovative Medicine | 55 | 67 | -17.9% |
| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA · Innovative Medicine | 312 | 321 | -2.8% |
| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA · Innovative Medicine | 85 | 117 | -27.4% |
| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA · Innovative Medicine | 396 | 438 | -9.6% |
| REMICADE · Innovative Medicine | 283 | 231 | +22.5% |
| REMICADE · Innovative Medicine | 34 | 35 | -2.9% |
| REMICADE · Innovative Medicine | 138 | 127 | +8.7% |
| REMICADE · Innovative Medicine | 455 | 393 | +15.8% |
| RYBREVANT + LAZCLUZE · Innovative Medicine | 139 | 52 | +167.3% |
| RYBREVANT + LAZCLUZE · Innovative Medicine | 41 | 17 | +141.2% |
| RYBREVANT + LAZCLUZE · Innovative Medicine | 179 | 69 | +159.4% |
| SIMPONI / SIMPONI ARIA · Innovative Medicine | 305 | 267 | +14.2% |
| SIMPONI / SIMPONI ARIA · Innovative Medicine | 387 | 270 | +43.3% |
| SIMPONI / SIMPONI ARIA · Innovative Medicine | 690 | 537 | +28.5% |
| SPINE, SPORTS & OTHER · MEDTECH | 422 | 430 | -1.9% |
| SPINE, SPORTS & OTHER · MEDTECH | 305 | 314 | -2.9% |
| SPINE, SPORTS & OTHER · MEDTECH | 727 | 743 | -2.2% |
| SPRAVATO · Innovative Medicine | 366 | 226 | +61.9% |
| SPRAVATO · Innovative Medicine | 50 | 44 | +13.6% |
| SPRAVATO · Innovative Medicine | 414 | 271 | +52.8% |
| STELARA · Innovative Medicine | 1,078 | 1,855 | -41.9% |
| STELARA · Innovative Medicine | 575 | 1,030 | -44.2% |
| STELARA · Innovative Medicine | 1,653 | 2,885 | -42.7% |
| SURGICAL · MEDTECH | 128 | 113 | +13.3% |
| SURGICAL · MEDTECH | 277 | 254 | +9.1% |
| SURGICAL · MEDTECH | 403 | 367 | +9.8% |
| TALVEY · Innovative Medicine | 82 | 59 | +39.0% |
| TALVEY · Innovative Medicine | 24 | 9 | +166.7% |
| TALVEY · Innovative Medicine | 106 | 69 | +53.6% |
| Tecvayli · Innovative Medicine | 114 | 104 | +9.6% |
| Tecvayli · Innovative Medicine | 52 | 30 | +73.3% |
| Tecvayli · Innovative Medicine | 166 | 135 | +23.0% |
| TRAUMA · MEDTECH | 501 | 498 | +0.6% |
| TRAUMA · MEDTECH | 267 | 260 | +2.7% |
| TRAUMA · MEDTECH | 768 | 759 | +1.2% |
| TREMFYA · Innovative Medicine | 796 | 589 | +35.1% |
| TREMFYA · Innovative Medicine | 391 | 317 | +23.3% |
| TREMFYA · Innovative Medicine | 1,186 | 906 | +30.9% |
| UPTRAVI · Innovative Medicine | 382 | 349 | +9.5% |
| UPTRAVI · Innovative Medicine | 94 | 76 | +23.7% |
| UPTRAVI · Innovative Medicine | 476 | 426 | +11.7% |
| XARELTO · Innovative Medicine | 621 | 587 | +5.8% |
| XARELTO · Innovative Medicine | 621 | 587 | +5.8% |
| ZYTIGA · Innovative Medicine | 6 | 11 | -45.5% |
| ZYTIGA · Innovative Medicine | 139 | 154 | -9.7% |
| ZYTIGA · Innovative Medicine | 145 | 165 | -12.1% |
Show Business Segments breakouts |
|||
| Innovative Medicine | 15,202 | 14,490 | +4.9% |
| Innovative Medicine · Cardiovascular / Metabolism / Other | 930 | 892 | +4.3% |
| Innovative Medicine · Immunology | 3,993 | 4,722 | -15.4% |
| Innovative Medicine · Infectious Diseases | 803 | 965 | -16.8% |
| Innovative Medicine · Neuroscience | 2,051 | 1,782 | +15.1% |
| Innovative Medicine · Non Us | 6,041 | 5,980 | +1.0% |
| Innovative Medicine · Non Us | 154 | 176 | -12.5% |
| Innovative Medicine · Non Us | 1,489 | 1,744 | -14.6% |
| Innovative Medicine · Non Us | 484 | 631 | -23.3% |
| Innovative Medicine · Non Us | 674 | 679 | -0.7% |
| Innovative Medicine · Non Us | 2,928 | 2,455 | +19.3% |
| Innovative Medicine · Non Us | 314 | 296 | +6.1% |
| Innovative Medicine · Oncology | 6,312 | 5,090 | +24.0% |
| Innovative Medicine · Operating Segments | 15,202 | 14,490 | +4.9% |
| Innovative Medicine · Pulmonary Hypertension | 1,113 | 1,039 | +7.1% |
| Innovative Medicine · US | 9,161 | 8,510 | +7.6% |
| Innovative Medicine · US | 776 | 717 | +8.2% |
| Innovative Medicine · US | 2,505 | 2,978 | -15.9% |
| Innovative Medicine · US | 320 | 334 | -4.2% |
| Innovative Medicine · US | 1,377 | 1,102 | +25.0% |
| Innovative Medicine · US | 3,385 | 2,636 | +28.4% |
| Innovative Medicine · US | 799 | 743 | +7.5% |
| MEDTECH | 8,541 | 7,957 | +7.3% |
| MEDTECH · ABIOMED | 448 | 379 | +18.2% |
| MEDTECH · Cardiovascular [Member] | 2,313 | 1,873 | +23.5% |
| MEDTECH · ELECTROPHYSIOLOGY | 1,468 | 1,323 | +11.0% |
| MEDTECH · Non Us | 4,158 | 3,898 | +6.7% |
| MEDTECH · Non Us | 89 | 72 | +23.6% |
| MEDTECH · Non Us | 948 | 753 | +25.9% |
| MEDTECH · Non Us | 728 | 618 | +17.8% |
| MEDTECH · Non Us | 885 | 890 | -0.6% |
| MEDTECH · Non Us | 72 | 64 | +12.5% |
| MEDTECH · Non Us | 58 | 0 | — |
| MEDTECH · Non Us | 1,512 | 1,493 | +1.3% |
| MEDTECH · Non Us | 813 | 763 | +6.6% |
| MEDTECH · Operating Segments | 8,541 | 7,957 | +7.3% |
| MEDTECH · Orthopaedics | 2,305 | 2,312 | -0.3% |
| MEDTECH · Other Cardiovascular | 104 | 93 | +11.8% |
| MEDTECH · Shockwave | 292 | 77 | +279.2% |
| MEDTECH · Surgery | 2,555 | 2,488 | +2.7% |
| MEDTECH · US | 4,383 | 4,059 | +8.0% |
| MEDTECH · US | 360 | 309 | +16.5% |
| MEDTECH · US | 1,364 | 1,119 | +21.9% |
| MEDTECH · US | 741 | 705 | +5.1% |
| MEDTECH · US | 1,420 | 1,422 | -0.1% |
| MEDTECH · US | 31 | 29 | +6.9% |
| MEDTECH · US | 233 | 77 | +202.6% |
| MEDTECH · US | 1,043 | 995 | +4.8% |
| MEDTECH · US | 557 | 523 | +6.5% |
| MEDTECH · Vision | 1,369 | 1,285 | +6.5% |
Show Geography breakouts |
|||
| Asia-Pacific, Africa | 3,606 | 3,452 | +4.5% |
| Europe | 5,387 | 5,214 | +3.3% |
| Non Us | 10,199 | 9,878 | +3.2% |
| US | 13,544 | 12,569 | +7.8% |
| Western Hemisphere, excluding U.S. | 1,206 | 1,212 | -0.5% |
| Sales Revenue Goods Net Percent To Sales | 100 | 100 | 0.0% |
| Cost of Revenue | 7,628 | 6,869 | +11.0% |
Show Business Segments breakouts |
|||
| Innovative Medicine · Operating Segments | 3,978 | 3,603 | +10.4% |
| MEDTECH · Operating Segments | 3,638 | 3,248 | +12.0% |
| Cost Of Goods Sold Percent To Sales | 32.1 | 30.6 | +4.9% |
| Gross Profit | 16,115 | 15,578 | +3.4% |
| Gross Profit Percent To Sales | 67.9 | 69.4 | -2.2% |
| Selling, General & Administrative | 5,889 | 5,681 | +3.7% |
Show Business Segments breakouts |
|||
| Innovative Medicine · Operating Segments | 2,789 | 2,665 | +4.7% |
| MEDTECH · Operating Segments | 2,862 | 2,671 | +7.2% |
| Selling General And Administrative Expense Percent To Sales | 24.8 | 25.3 | -2.0% |
| Research And Development Expense Excluding Acquired In Process Cost | 3,516 | 3,440 | +2.2% |
Show Business Segments breakouts |
|||
| Innovative Medicine · Operating Segments | 2,869 | 2,722 | +5.4% |
| MEDTECH · Operating Segments | 647 | 718 | -9.9% |
| Research And Development Expense Excluding Acquired In Process Cost Percent To Sales | 14.8 | 15.3 | -3.3% |
| Interest Income | -260 | -395 | +34.2% |
| Investment Income Interest Percent To Sales | -1.1 | -1.8 | +38.9% |
| Interest Expense | 308 | 270 | +14.1% |
| Interest Expense Percent To Sales | 1.3 | 1.2 | +8.3% |
| Other Non-Operating Income (Expense) | 107 | 653 | -83.6% |
Show Business Segments breakouts |
|||
| Innovative Medicine · Operating Segments | -14 | -41 | +65.9% |
| MEDTECH · Operating Segments | -190 | -231 | +17.7% |
| Other Non Operating Income Expense Percent To Sales | 0.5 | 2.9 | -82.8% |
| Restructuring Charges | 64 | -13 | +592.3% |
Show Business Segments breakouts |
|||
| MEDTECH | 0.1 | 0.1 | 0.0% |
| MedTech Surgery Franchise · Operating Segments | 29 | — | — |
| MEDTECH · Costs of Goods and Services Sold | 15 | 2 | +650.0% |
| MEDTECH · Operating Segments | 50 | 52 | -3.8% |
| MEDTECH · Restructuring Charges | 35 | 50 | -30.0% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 79 | -11 | +818.2% |
Show Restructuring Plan breakouts |
|||
| MedTech Surgery Franchise | 29 | — | — |
| Restructuringchargepercenttosales | 0.3 | 0 | — |
| Income Before Taxes | 6,491 | 5,748 | +12.9% |
Show Business Segments breakouts |
|||
| Innovative Medicine · Operating Segments | 5,552 | 5,459 | +1.7% |
| MEDTECH · Operating Segments | 1,204 | 1,089 | +10.6% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 6,756 | 6,548 | +3.2% |
| Income Loss From Continuing Operations Before Income Taxes Noncontrolling Interest Percent To Sales | 27.3 | 25.6 | +6.6% |
| Income Tax Expense (Benefit) | 954 | 1,062 | -10.2% |
| Income Tax Expense Benefit Percent To Sales | 4 | 4.7 | -14.9% |
| Income Loss From Continuing Operations Net Of Tax Attributable To Parent Percent Of Sales | 23.3 | 20.9 | +11.5% |
| Net Income | 5,537 | 4,686 | +18.2% |
Show Equity Components breakouts |
|||
| Retained Earnings | 5,537 | 4,686 | +18.2% |
| EPS (Basic) | 2.3 | 1.95 | +17.9% |
| EPS (Diluted) | 2.29 | 1.93 | +18.7% |
| Wtd Avg Shares (Basic) | 2,406.3 | 2,406.8 | -0.0% |
| Wtd Avg Shares (Diluted) | 2,419.1 | 2,422 | -0.1% |
| Comprehensive Income | 2,972 | 4,201 | -29.3% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax | 25 | 75 | -66.7% |
Balance Sheet
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 18,577 | 24,878 | -25.3% |
Show Information By Category Of Debt Security breakouts |
|||
| Availableforsale Securities | 1,791 | 6,243 | -71.3% |
| Availableforsale Securities · Corporate Debt Securities | 38 | 61 | -37.7% |
| Availableforsale Securities · Sovereign Debt Securities | 94 | — | — |
| Availableforsale Securities · US Treasury And Government | 1,659 | 6,182 | -73.2% |
| Heldtomaturity Securities | 16,786 | 18,635 | -9.9% |
| Heldtomaturity Securities · Bank Time Deposits | 863 | 859 | +0.5% |
| Heldtomaturity Securities · Cash | 3,246 | 4,247 | -23.6% |
| Heldtomaturity Securities · Money Market Funds | 4,637 | 4,883 | -5.0% |
| Heldtomaturity Securities · Securities Loaned Or Sold Under Agreements To Repurchase | 8,040 | 8,496 | -5.4% |
| Marketable Securities (Current) | 303 | 597 | -49.2% |
Show Information By Category Of Debt Security breakouts |
|||
| Availableforsale Securities | 303 | 597 | -49.2% |
| Availableforsale Securities · Corporate Debt Securities | 190 | 181 | +5.0% |
| Availableforsale Securities · Sovereign Debt Securities | 99 | 2 | +4850.0% |
| Availableforsale Securities · US Treasury And Government | 14 | 403 | -96.5% |
| Accounts Receivable | 17,846 | 15,794 | +13.0% |
| Inventory | 13,412 | 12,169 | +10.2% |
| Prepaid Expenses & Other Current Assets | 4,360 | 4,379 | -0.4% |
| Total Current Assets | 54,498 | 57,817 | -5.7% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 21,949 | 19,748 | +11.1% |
| Goodwill | 48,117 | — | — |
Show Business Segments breakouts |
|||
| Innovative Medicine | 14,326 | — | — |
| MEDTECH | 33,791 | — | — |
| Deferred Tax Assets | 6,801 | 9,004 | -24.5% |
| Other Non-Current Assets | 12,189 | 10,544 | +15.6% |
Show Fair Value By Asset Class breakouts |
|||
| Equity Securities · Equity Investments with readily determinable value | 453 | 470 | -3.6% |
| Equity Securities · Equity Investments without readily determinable value | 823 | 673 | +22.3% |
| Total Assets | 193,389 | — | — |
Show Business Segments breakouts |
|||
| General Corporate · Corporate Non Segment | 31,157 | — | — |
| Innovative Medicine · Operating Segments | 75,487 | — | — |
| MEDTECH · Operating Segments | 86,745 | — | — |
| Segments Total | 162,232 | — | — |
| Intangible Assets (Q) | — | — | — |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Other Intangible Assets | 7,423 | 7,158 | +3.7% |
| Patents And Trademarks | 22,516 | 18,603 | +21.0% |
| Marketable Securities (Non-Current) (Q) | — | — | — |
Show Fair Value By Asset Class breakouts |
|||
| Equity Securities · Equity Investments with readily determinable value | 453 | 470 | -3.6% |
| Other Assets | |||
| Property Plant And Equipment Gross | 52,472 | 48,035 | +9.2% |
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | -30,523 | -28,287 | -7.9% |
| Intangible Assets Net Excluding Goodwill | 49,835 | 39,725 | +25.4% |
| Current Liabilities | |||
| Short Term Borrowings | 11,526 | 9,855 | +17.0% |
Show Fair Value By Measurement Basis breakouts |
|||
| Carrying Reported Amount Fair Value Disclosure | 11,526 | 9,855 | +17.0% |
| Estimate Of Fair Value Fair Value Disclosure | 11,495 | 9,835 | +16.9% |
Show Short Term Debt Type breakouts |
|||
| Commercial Paper | 8.5 | 8.5 | 0.0% |
| Accounts Payable | 9,464 | 8,848 | +7.0% |
| Accrued Liabilities | 7,404 | 10,539 | -29.7% |
| Accrued Rebates Returns And Promotions | 20,823 | 17,539 | +18.7% |
| Employee Related Liabilities Current | 3,298 | 2,843 | +16.0% |
| Accrued Income Taxes Current | 1,665 | 4,309 | -61.4% |
| Total Current Liabilities | 54,180 | 53,933 | +0.5% |
| Non-Current Liabilities | |||
| Long-Term Debt | 39,235 | 31,636 | +24.0% |
Show Debt Instrument breakouts |
|||
| 0.95% Notes due 2027 · Carrying Reported Amount Fair Value Disclosure | 1,478 | 1,430 | +3.4% |
| 0.95% Notes due 2027 · Estimate Of Fair Value Fair Value Disclosure | 1,410 | 1,334 | +5.7% |
| 1.150% Notes due 2028 (750MM Euro 1.1704) · Carrying Reported Amount Fair Value Disclosure | 881 | 801 | +10.0% |
| 1.150% Notes due 2028 (750MM Euro 1.1704) · Estimate Of Fair Value Fair Value Disclosure | 843 | 744 | +13.3% |
| 1.30% Notes due 2030 · Carrying Reported Amount Fair Value Disclosure | 1,676 | 1,626 | +3.1% |
| 1.30% Notes due 2030 · Estimate Of Fair Value Fair Value Disclosure | 1,521 | 1,445 | +5.3% |
| 1.650% Notes due 2035 (1.5B Euro 1.1704) · Carrying Reported Amount Fair Value Disclosure | 1,756 | 1,597 | +10.0% |
| 1.650% Notes due 2035 (1.5B Euro 1.1704) · Estimate Of Fair Value Fair Value Disclosure | 1,528 | 1,384 | +10.4% |
| 2.10% Notes due 2040 · Carrying Reported Amount Fair Value Disclosure | 885 | 836 | +5.9% |
| 2.10% Notes due 2040 · Estimate Of Fair Value Fair Value Disclosure | 684 | 670 | +2.1% |
| 2.25% Notes due 2050 · Carrying Reported Amount Fair Value Disclosure | 851 | 807 | +5.5% |
| 2.25% Notes due 2050 · Estimate Of Fair Value Fair Value Disclosure | 580 | 593 | -2.2% |
| 2.45% Notes due 2060 · Carrying Reported Amount Fair Value Disclosure | 1,102 | 1,055 | +4.5% |
| 2.45% Notes due 2060 · Estimate Of Fair Value Fair Value Disclosure | 694 | 707 | -1.8% |
| 2.700% Notes Due February 2029 · Carrying Reported Amount Fair Value Disclosure | 706 | — | — |
| 2.700% Notes Due February 2029 · Estimate Of Fair Value Fair Value Disclosure | 708 | — | — |
| 2.90% Notes due 2028 · Carrying Reported Amount Fair Value Disclosure | 1,498 | 1,497 | +0.1% |
| 2.90% Notes due 2028 · Estimate Of Fair Value Fair Value Disclosure | 1,460 | 1,418 | +3.0% |
| 2.95% Notes due 2027 · Carrying Reported Amount Fair Value Disclosure | 950 | 902 | +5.3% |
| 2.95% Notes due 2027 · Estimate Of Fair Value Fair Value Disclosure | 984 | 955 | +3.0% |
| 3.050% Notes Due February 2033 · Carrying Reported Amount Fair Value Disclosure | 822 | — | — |
| 3.050% Notes Due February 2033 · Estimate Of Fair Value Fair Value Disclosure | 822 | — | — |
| 3.20% Notes due 2032 (700MM Euro 1.0721) · Carrying Reported Amount Fair Value Disclosure | 821 | 747 | +9.9% |
| 3.20% Notes due 2032 (700MM Euro 1.0721) · Estimate Of Fair Value Fair Value Disclosure | 834 | 750 | +11.2% |
| 3.35% Notes Due 2036 (800MM Euro 1.0721) · Carrying Reported Amount Fair Value Disclosure | 937 | 852 | +10.0% |
| 3.35% Notes Due 2036 (800MM Euro 1.0721) · Estimate Of Fair Value Fair Value Disclosure | 939 | 853 | +10.1% |
| 3.350% Notes Due February 2037 · Carrying Reported Amount Fair Value Disclosure | 1,175 | — | — |
| 3.350% Notes Due February 2037 · Estimate Of Fair Value Fair Value Disclosure | 1,160 | — | — |
| 3.40% Notes due 2038 · Carrying Reported Amount Fair Value Disclosure | 993 | 993 | 0.0% |
| 3.40% Notes due 2038 · Estimate Of Fair Value Fair Value Disclosure | 857 | 839 | +2.1% |
| 3.50% Notes due 2048 · Carrying Reported Amount Fair Value Disclosure | 744 | 743 | +0.1% |
| 3.50% Notes due 2048 · Estimate Of Fair Value Fair Value Disclosure | 567 | 579 | -2.1% |
| 3.55% Notes Due 2044 (1.0B Euro 1.0721) · Carrying Reported Amount Fair Value Disclosure | 1,103 | 1,062 | +3.9% |
| 3.55% Notes Due 2044 (1.0B Euro 1.0721) · Estimate Of Fair Value Fair Value Disclosure | 1,135 | 1,062 | +6.9% |
| 3.587% Notes due 2036 · Carrying Reported Amount Fair Value Disclosure | 905 | 855 | +5.8% |
| 3.587% Notes due 2036 · Estimate Of Fair Value Fair Value Disclosure | 902 | 876 | +3.0% |
| 3.600% Notes Due February 2045 · Carrying Reported Amount Fair Value Disclosure | 819 | — | — |
| 3.600% Notes Due February 2045 · Estimate Of Fair Value Fair Value Disclosure | 792 | — | — |
| 3.625% Notes due 2037 · Carrying Reported Amount Fair Value Disclosure | 1,396 | 1,346 | +3.7% |
| 3.625% Notes due 2037 · Estimate Of Fair Value Fair Value Disclosure | 1,334 | 1,310 | +1.8% |
| 3.700% Notes Due February 2055 · Carrying Reported Amount Fair Value Disclosure | 1,172 | — | — |
| 3.700% Notes Due February 2055 · Estimate Of Fair Value Fair Value Disclosure | 1,118 | — | — |
| 3.73% Notes due 2046 · Carrying Reported Amount Fair Value Disclosure | 1,979 | 1,978 | +0.1% |
| 3.73% Notes due 2046 · Estimate Of Fair Value Fair Value Disclosure | 1,592 | 1,609 | -1.1% |
| 3.75% Notes due 2047 · Carrying Reported Amount Fair Value Disclosure | 863 | 816 | +5.8% |
| 3.75% Notes due 2047 · Estimate Of Fair Value Fair Value Disclosure | 798 | 805 | -0.9% |
| 4.375% Notes due 2033 · Carrying Reported Amount Fair Value Disclosure | 853 | 854 | -0.1% |
| 4.375% Notes due 2033 · Estimate Of Fair Value Fair Value Disclosure | 847 | 835 | +1.4% |
| 4.50% Notes due 2027 · Carrying Reported Amount Fair Value Disclosure | 749 | — | — |
| 4.50% Notes due 2027 · Estimate Of Fair Value Fair Value Disclosure | 757 | — | — |
| 4.50% Notes due 2040 · Carrying Reported Amount Fair Value Disclosure | 542 | 541 | +0.2% |
| 4.50% Notes due 2040 · Estimate Of Fair Value Fair Value Disclosure | 523 | 521 | +0.4% |
| 4.50% Notes due 2043 · Carrying Reported Amount Fair Value Disclosure | 496 | 496 | 0.0% |
| 4.50% Notes due 2043 · Estimate Of Fair Value Fair Value Disclosure | 459 | 470 | -2.3% |
| 4.55% Notes Due 2029 · Carrying Reported Amount Fair Value Disclosure | 748 | — | — |
| 4.55% Notes Due 2029 · Estimate Of Fair Value Fair Value Disclosure | 762 | — | — |
| 4.70% Notes due 2030 · Carrying Reported Amount Fair Value Disclosure | 995 | — | — |
| 4.70% Notes due 2030 · Estimate Of Fair Value Fair Value Disclosure | 1,022 | — | — |
| 4.80% Notes due 2029 · Carrying Reported Amount Fair Value Disclosure | 1,146 | 1,145 | +0.1% |
| 4.80% Notes due 2029 · Estimate Of Fair Value Fair Value Disclosure | 1,181 | 1,161 | +1.7% |
| 4.85% Notes Due 2032 · Carrying Reported Amount Fair Value Disclosure | 1,242 | — | — |
| 4.85% Notes Due 2032 · Estimate Of Fair Value Fair Value Disclosure | 1,281 | — | — |
| 4.85% Notes due 2041 · Carrying Reported Amount Fair Value Disclosure | 298 | 297 | +0.3% |
| 4.85% Notes due 2041 · Estimate Of Fair Value Fair Value Disclosure | 291 | 293 | -0.7% |
| 4.90% Notes due 2031 · Carrying Reported Amount Fair Value Disclosure | 1,146 | 1,145 | +0.1% |
| 4.90% Notes due 2031 · Estimate Of Fair Value Fair Value Disclosure | 1,189 | 1,161 | +2.4% |
| 4.95% Notes due 2033 · Carrying Reported Amount Fair Value Disclosure | 499 | 499 | 0.0% |
| 4.95% Notes due 2033 · Estimate Of Fair Value Fair Value Disclosure | 517 | 513 | +0.8% |
| 4.95% Notes due 2034 · Carrying Reported Amount Fair Value Disclosure | 847 | 846 | +0.1% |
| 4.95% Notes due 2034 · Estimate Of Fair Value Fair Value Disclosure | 880 | 860 | +2.3% |
| 5.00% Notes due 2035 · Carrying Reported Amount Fair Value Disclosure | 1,244 | — | — |
| 5.00% Notes due 2035 · Estimate Of Fair Value Fair Value Disclosure | 1,282 | — | — |
| 5.25% Notes due 2054 · Carrying Reported Amount Fair Value Disclosure | 843 | 843 | 0.0% |
| 5.25% Notes due 2054 · Estimate Of Fair Value Fair Value Disclosure | 837 | 854 | -2.0% |
| 5.85% Notes due 2038 · Carrying Reported Amount Fair Value Disclosure | 697 | 697 | 0.0% |
| 5.85% Notes due 2038 · Estimate Of Fair Value Fair Value Disclosure | 761 | 756 | +0.7% |
| 5.95% Notes due 2037 · Carrying Reported Amount Fair Value Disclosure | 994 | 994 | 0.0% |
| 5.95% Notes due 2037 · Estimate Of Fair Value Fair Value Disclosure | 1,103 | 1,089 | +1.3% |
| 6.95% Notes due 2029 · Carrying Reported Amount Fair Value Disclosure | 299 | 298 | +0.3% |
| 6.95% Notes due 2029 · Estimate Of Fair Value Fair Value Disclosure | 334 | 332 | +0.6% |
| Other · Carrying Reported Amount Fair Value Disclosure | 85 | 67 | +26.9% |
| Other · Estimate Of Fair Value Fair Value Disclosure | 88 | 67 | +31.3% |
Show Fair Value By Measurement Basis breakouts |
|||
| Carrying Reported Amount Fair Value Disclosure | 39,235 | 31,636 | +24.0% |
| Estimate Of Fair Value Fair Value Disclosure | 37,376 | 29,716 | +25.8% |
| Deferred Tax Liabilities | 3,799 | 2,635 | +44.2% |
| Employee Related Liabilities Current And Noncurrent | 7,021 | 6,919 | +1.5% |
| Accrued Income Taxes Noncurrent | 418 | 341 | +22.6% |
| Other Non-Current Liabilities | 10,263 | 14,086 | -27.1% |
| Total Liabilities | 114,916 | 109,550 | +4.9% |
| Stockholders' Equity | |||
| Common Stock | 3,120 | 3,120 | 0.0% |
| Accumulated Other Comprehensive Income | -14,305 | -11,253 | -27.1% |
| Retained Earnings | 165,371 | 155,360 | +6.4% |
| Treasury Stock Common Value | 75,713 | 75,689 | 0.0% |
| Total Stockholders' Equity | 78,473 | 71,538 | +9.7% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 78,473 | 71,538 | +9.7% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -1,466 | -1,939 | +24.4% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -659 | -899 | +26.7% |
| Accumulated Net Unrealized Investment Gain Loss | 0 | 0 | — |
| Accumulated Other Comprehensive Income | -14,305 | -11,253 | -27.1% |
| Accumulated Translation Adjustment | -12,180 | -8,415 | -44.7% |
| Common Stock | 3,120 | 3,120 | 0.0% |
| Retained Earnings | 165,371 | 155,360 | +6.4% |
| Treasury Stock Common | -75,713 | -75,689 | -0.0% |
| Total Liabilities & Equity | 193,389 | 181,088 | +6.8% |
Cash Flow Statement
| Metric | YTD Q2 2025 | YTD Q2 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 3,715 | 3,597 | +3.3% |
Show Business Segments breakouts |
|||
| General Corporate · Corporate Non Segment | 112 | 184 | -39.1% |
| Innovative Medicine · Operating Segments | 1,925 | 1,861 | +3.4% |
| MEDTECH · Operating Segments | 1,678 | 1,552 | +8.1% |
| Segments Total | 3,603 | 3,413 | +5.6% |
| Stock-Based Compensation | 698 | 643 | +8.6% |
| Asset Impairment Charges | 30 | 379 | -92.1% |
| In Process Research And Development Charge | 92 | — | — |
| Gain Loss On Sales Of Assets And Asset Impairment Charges | -74 | -223 | +66.8% |
| Deferred Income Taxes | 2,997 | -2,257 | +232.8% |
| Provision For Doubtful Accounts | 3 | — | — |
| Change in Accounts Receivable | -2,283 | -1,163 | -96.3% |
| Change in Inventory | -656 | -739 | +11.2% |
| Increase Decrease In Accounts Payable And Accrued Liabilities | -886 | 449 | -297.3% |
| Increase Decrease In Other Operating Assets | -6,194 | 3,731 | -266.0% |
| Increase Decrease In Other Operating Liabilities | -5,926 | -3,068 | -93.2% |
| Net Cash from Operations | 8,052 | 9,290 | -13.3% |
| Investing Activities | |||
| Capital Expenditures | -1,838 | -1,783 | -3.1% |
| Proceeds From Sale Of Productive Assets | 332 | 573 | -42.1% |
| Payments To Acquire Businesses Net Of Cash Acquired | -14,458 | -14,807 | +2.4% |
| Payments To Acquire In Process Research And Development Assets | -369 | — | — |
| Payments To Acquire Investments | -431 | -1,184 | +63.6% |
| Proceeds From Sale Maturity And Collections Of Investments | 953 | 1,706 | -44.1% |
| Proceeds Payments From To Credit Support Agreements Investing Activities | -2,684 | 1,430 | -287.7% |
| Other Investing Activities | -66 | -86 | +23.3% |
| Net Cash from Investing | -18,561 | -14,151 | -31.2% |
| Financing Activities | |||
| Payments Of Ordinary Dividends | -6,118 | -5,854 | -4.5% |
| Share Repurchases | -2,127 | -1,611 | -32.0% |
| Proceeds From Short Term Debt | 9,349 | 13,976 | -33.1% |
| Repayments Of Short Term Debt | -5,058 | -3,915 | -29.2% |
| Proceeds From Issuance Of Long Term Debt | 9,138 | 6,659 | +37.2% |
| Repayments Of Senior Debt | -754 | -803 | +6.1% |
| Proceeds From Exercise Of Stock Options And Excess Tax Benefits | 557 | 290 | +92.1% |
| Proceeds Payments From To Credit Support Agreements Financing Activities | -271 | 281 | -196.4% |
| Proceeds From Payments For Other Financing Activities | 41 | 37 | +10.8% |
| Net Cash from Financing | 4,757 | 8,090 | -41.2% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 224 | -210 | +206.7% |
| Net Change in Cash | -5,528 | 3,019 | -283.1% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 18,577 | 24,878 | -25.3% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.